News

In the SURF302 trial, favorable response rates were seen in the single- and multiple-marker-lesion population, justifying further investigation in the adjuvant bladder cancer setting.

Purpose-built decentralized oncology trials bring new therapies to community clinics, expanding access and showing trials aren’t just last resort.

During a live Case-Based Roundtable event, Brea Lipe, MD, and participants discussed treatment options for an older patient who already received multiple bispecific antibodies for multiple myeloma.

Mipletamig plus venetoclax and azacitidine delivers 93% clinical benefit in TP53-mutated frontline AML, fueling hopes for a new option.

Scaling back thyroid ultrasonography referrals may meaningfully reduce diagnoses without affecting survival.

The FDA granted accelerated approval to sevabertinib for HER2-mutant, nonsquamous NSCLC regardless of prior systemic therapy, based on SOHO-01 trial data.

In the pivotal phase 2 QUINTESSENTIAL trial, arlo-cel, a GPRC5D-targeted CAR T-cell therapy, showed favorable overall response rate in patients who had received multiple prior lines including BCMA-targeted therapy.

A City of Hope study found success in promoting skin cancer screening to transplant survivors, Saro Armenian, MD, explains.

During a live event, Sudarsan Kollimuttathuillam, MD, and participants discussed how anemia and thrombocytopenia in extensive-stage small cell lung cancer are still managed one lineage, and one crisis, at a time.

OST-HER2, an investigational immunotherapy, yielded favorable overall survival outcomes ahead of an FDA meeting to consider its basis for approval.

DeLLphi-305 data show tarlatamab plus durvalumab significantly improved overall survival as first-line maintenance in extensive stage small cell lung cancer.

New data set reveals Asian American breast cancer survival advantage persists despite reproductive, lifestyle, neighborhood, and treatment factors, highlighting crucial ethnic and nativity differences.

U.S. alcohol-linked cancer deaths double since 1990, led by surging liver cancer; men, older adults hit hardest, with wide state-by-state gaps.

Next-gen T‑cell immunotherapies tackle resistance and expand access, as bispecifics, trispecifics, and off‑the‑shelf or in vivo CAR T move earlier.

The FDA also approved the Guardant360 CDx assay as a companion diagnostic to identify eligible patients for the camizestrant regimen.

Published results from the PARADIGM study of azacitidine/venetoclax showed an event-free survival benefit and lower hemorrhage rates in acute myeloid leukemia.

ALINA trial shows adjuvant alectinib after ALK+ lung cancer surgery improves quality of life, with manageable safety and durable DFS.

AUA/SUO's 2026 NMIBC guideline amendment adds 40 statements on risk stratification, surveillance intervals, urinary biomarkers, and emerging BCG-unresponsive therapies.

Phase 3 Neo-Healer shows anbenitamab plus HB1801 boosts complete response rates in ERBB2-positive breast cancer, with manageable safety.

The study also identified a link between early fatigue and eventual response to CAR-T.

Clinicians weigh acalabrutinib vs zanubrutinib for relapsed CLL, focusing on adverse effects, trial data, and where pirtobrutinib fits next.

Ivonescimab extends survival and doubles PFS vs pembrolizumab in first-line PD‑L1+ metastatic NSCLC, with manageable safety.

Etentamig surpassed standard therapy in terms of response rate and progression-free survival in the phase 3 CERVINO trial for relapsed/refractory multiple myeloma.

A new CIRI2-CLL model uses MRD and clinical data to better predict CLL survival after fixed-duration therapy, enabling personalized risk stratification.

Daraxonrasib showed dose-dependent objective response rates of 31% to 37% in previously treated RAS-mutant NSCLC, per phase 1/2 trial data published in the New England Journal of Medicine.

During a virtual event, Eric K. Singhi, MD, and participants discussed how the ROS1 G2032R resistance mutation is guiding second-line therapy selection in ROS1-positive advanced non–small cell lung cancer.

Rezatapopt hit a 46% ORR in TP53 Y220C–mutated ovarian cancer in the PYNNACLE trial, with an FDA filing expected in Q1 2027.

FDA grants breakthrough status to JBS-003 F-MISO PET imaging, aiming to personalize radiation in HPV-positive throat cancer by safely reducing dose for nonhypoxic tumors.